(P144) Radiation-Associated Toxicities in Obese Women With Endometrial Cancer: More Than Just BMI?

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

The impact of obesity on adjuvant treatment is poorly understood. Increasing BMI was associated with increased frequency of gynecologic and cutaneous radiation-associated toxicities. Additional studies to critically evaluate the radiation treatment dosing and treatment fields in obese EC patients are warranted to identify strategies to mitigate the radiation-associated toxicities in these women.

Savita Dandapani, MD, PhD, Ying Zhang, MD, Richard Jennelle, MD, Yvonne Lin, MD; City of Hope; USC

PURPOSE: The current study characterizes the impact of obesity on postoperative radiation-associated toxicities in women with endometrial cancer (EC).

MATERIALS AND METHODS: A retrospective cohort study identified 96 women with EC referred to a large urban institution’s radiation oncology practice for postoperative whole-pelvic radiotherapy (WPRT) and/or intracavitary vaginal brachytherapy (ICBT). Demographic, clinicopathologic, and patient-reported toxicity data were obtained from medical records. Anthropometric information, including body mass index (BMI), was collected from nursing intake records at each clinic visit. Radiation-related toxicities were graded according to Radiation Therapy Oncology Group (RTOG) Acute Radiation Morbidity Scoring Criteria. The follow-up period ranged from 1 month to 11 years (median 2 yr). The data were analyzed by chi-square, logistic regression, and recursive partitioning analyses.

RESULTS: A total of 68 evaluable EC patients who received WPRT and/or ICBT were included in the primary analysis. The median age was 52 years (range: 29–73 yr). The majority of patients were Hispanic (48, 71%), with 6 (9%) Caucasian, 1 (1%) African-American, and 13 (19%) Asian. The median BMI at diagnosis was 34.5 kg/m2 (range: 20.5–56.6 kg/m2). A total of 58 patients (85%) had abdominal hysterectomies, and 10 (15%) had laparoscopic hysterectomies; 43(63%) had a pelvic lymphadenectomy, and 15 (22%) had para-aortic lymphadenectomies. BMI was independently associated with reported radiation-related cutaneous toxicities (P = .022) and gynecologic toxicities (P = .027). Younger women also reported more gynecologic toxicities (P = .039). Adjuvant radiation technique was associated with increased gastrointestinal- and genitourinary-related toxicities but not gynecologic toxicity. There was no association of International Federation of Gynecology and Obstetrics (FIGO) stage, use of adjuvant chemotherapy, or hysterectomy type with reported radiation toxicities.

CONCLUSIONS: The impact of obesity on adjuvant treatment is poorly understood. Increasing BMI was associated with increased frequency of gynecologic and cutaneous radiation-associated toxicities. Additional studies to critically evaluate the radiation treatment dosing and treatment fields in obese EC patients are warranted to identify strategies to mitigate the radiation-associated toxicities in these women.

Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Recent Videos
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.
Barriers to access and financial toxicities are challenges that must be addressed for CAR T-cell therapies in LBCL, according to Jose Sandoval Sus, MD.
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Long-term toxicities like infections and secondary primary malignancies remain a concern when sequencing novel agents for those with multiple myeloma.
Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
Related Content